Literature DB >> 12042265

A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.

John K Jain1, Caryn Dutton, Bryna Harwood, Karen R Meckstroth, Daniel R Mishell.   

Abstract

BACKGROUND: Vaginal misoprostol has been shown to be an effective single agent for medical abortion. This randomized, double-blinded, placebo-controlled trial compared a regimen of mifepristone and misoprostol with misoprostol alone for termination of early pregnancy.
METHODS: 250 women with gestations < or = 56 days were randomized by a random number table to receive either 200 mg mifepristone orally or placebo followed 48 h later by 800 microg vaginal misoprostol. Administration of misoprostol was repeated every 24 h up to three doses if abortion failed to occur. Abortion success was defined as complete abortion without the use of surgical aspiration.
RESULTS: Successful medical abortions occurred in 114 out of 119 subjects (95.7%) after mifepristone followed by vaginal misoprostol. In all, 110 out of 125 subjects (88.0%) successfully aborted after placebo and vaginal misoprostol. The higher success rate of complete abortion with the mifepristone and misoprostol regimen was statistically significant compared with the placebo and misoprostol regimen (P < 0.05).
CONCLUSIONS: A regimen of mifepristone and misoprostol was significantly more effective for termination of pregnancies < or = 56 days than misoprostol alone. The 88% efficacy obtained with vaginal misoprostol alone may be clinically acceptable when mifepristone is not available.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042265     DOI: 10.1093/humrep/17.6.1477

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  13 in total

1.  Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review.

Authors:  Elizabeth G Raymond; Margo S Harrison; Mark A Weaver
Journal:  Obstet Gynecol       Date:  2019-01       Impact factor: 7.661

Review 2.  Medical methods for first trimester abortion.

Authors:  Jing Zhang; Kunyan Zhou; Dan Shan; Xiaoyan Luo
Journal:  Cochrane Database Syst Rev       Date:  2022-05-24

3.  The potential of medical abortion to reduce maternal mortality in Africa: what benefits for Tanzania and Ethiopia?

Authors:  Rebecca F Baggaley; Joanna Burgin; Oona M R Campbell
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

Review 4.  Medical treatments for incomplete miscarriage (less than 24 weeks).

Authors:  James P Neilson; Gillian Ml Gyte; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

Review 6.  Medical methods for first trimester abortion.

Authors:  Regina Kulier; Nathalie Kapp; A Metin Gülmezoglu; G Justus Hofmeyr; Linan Cheng; Aldo Campana
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 7.  Treatment Options After a Diagnosis of Early Miscarriage: Expectant, Medical, and Surgical.

Authors:  Thabea Musik; Juliane Grimm; Ingolf Juhasz-Böss; Elke Bäz
Journal:  Dtsch Arztebl Int       Date:  2021-11-19       Impact factor: 5.594

8.  Brazilian obstetrician-gynecologists and abortion: a survey of knowledge, opinions and practices.

Authors:  Lisa A Goldman; Sandra G García; Juan Díaz; Eileen A Yam
Journal:  Reprod Health       Date:  2005-11-15       Impact factor: 3.223

9.  Self-administered versus provider-administered medical abortion.

Authors:  Katherine Gambir; Caron Kim; Kelly Ann Necastro; Bela Ganatra; Thoai D Ngo
Journal:  Cochrane Database Syst Rev       Date:  2020-03-09

10.  How to assess success of treatment when using multiple doses: the case of misoprostol for medical abortion.

Authors:  Armando H Seuc; Iqbal H Shah; Moazzam Ali; Claudia Diaz-Olavarrieta; Marleen Temmerman
Journal:  Trials       Date:  2015-11-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.